CUDC907 1339928-25-4

1.Inquiries will be replied within 24 hours
2.We could supply various packages as you required
3.To protect the profit of our agents, price will not show on website, please send inquiries to get the price.
4.Fast delivery, goods arrive your office within 3 to 5 days
5.Please click "Inquiry" or "Email" below to get the price
white powder
Chemical Formula
Molecular Weight
Storage and Stability
in stock
CUDC-907 potently inhibits class I PI3Ks as well as classes I and II HDAC enzymes with IC50 of 1.7/5.0/1.8/2.8 nM and 19/54/39 nM for HDAC1/2/3/10 and PI3Kα/β/δ, respectively. IC50 & Target: IC50: 1.7/5.0/1.8/2.8 nM (HDAC1/2/3/10), 19/54/39 nM (PI3Kα/β/δ)[1] In Vitro: CUDC-907 is a potent pan-inhibitor of HDAC classes I and II enzymes and observed that its potency against class I HDACs is similar to that of panobinostat and greater than that of vorinostat. CUDC-907 is also a potent inhibitor of class I PI3K kinases with an IC50 of 19, 54, and 39 nM for PI3Kα, PI3Kβ, and PI3Kδ, respectively. CUDC-907 markedly induces p21 protein in H460, a non-small cell lung cancer (NSCLC) cell line. CUDC-907 causes the reduction of both p-STAT3 (Y-705) and p-SRC in RPMI-8226 multiple myeloma cells and reduces both phosphorylated and total protein levels of MET and EGFR as well as HER2 and HER3 in H1975 NSCLC cells and BT-474 breast cancer cells, respectively. CUDC-907 induces caspase-3 and -7 activation in HCT-116 colon cancer cells in a dose-dependent manner. CUDC-907 potently inhibits the growth of cancer cells derived from both hematologic and solid tumors. CUDC-907 potently inhibits the proliferation of cells expressing either mutant or wild-type PI3K[1]In Vivo: Oral administration of CUDC-907 inhibits growth of the Daudi cancer cell xenografts in a dose-dependent manner. Tumor stasis is observed at 100 mg/kg in this model without obvious toxicity. Importantly, in the same model, CUDC-907 achieves better efficacy than GDC-0941, Vorinostat, or a combination of these 2 compounds given at their maximal tolerated doses (MTD). Furthermore, CUDC-907 causes tumor regression or stasis after intravenous (50 mg/kg) or oral administration (100 mg/kg) in a xenograft tumor model of SU-DHL4 diffuse large B-cell lymphoma (DLBCL) and causes tumor stasis in KRAS-mutant A549 NSCLC cell xenografts[1].

Thank you for your company product support!

CAS No. :

Product Name :

Number :

Your name:



The company or laboratory name: